Barinthus Biotherapeutics (BRNS) Shares Outstanding (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has 7 years of Shares Outstanding (Entity) data on file, last reported at $40.8 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 1.26% year-over-year to $40.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.8 million (up 1.26% YoY) and the FY2025 annual result came in at $40.8 million, up 1.53% from the prior year.
• Shares Outstanding (Entity) steadied at $40.8 million in Q1 2026, from $40.8 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $40.8 million in Q4 2025 to a low of $37.2 million in Q1 2022.
• A 5-year average of $39.1 million and a median of $39.0 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) soared 352.24% — and 2026, when it grew 1.26%.
• Tracing BRNS's Shares Outstanding (Entity) over 5 years: stood at $37.7 million in 2022, then advanced by 2.55% to $38.6 million in 2023, then advanced by 4.12% to $40.2 million in 2024, then gained by 1.53% to $40.8 million in 2025, then changed by 0.0% to $40.8 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $40.8 million (Q1 2026), $40.8 million (Q4 2025), and $40.8 million (Q3 2025), per Business Quant data.